Investment Thesis

McKesson Corporation is a BUY at the current price of $747.23, as the market is significantly undervaluing its long-term growth potential and competitive advantages in the healthcare distribution industry. The company stands to benefit from structural shifts in healthcare delivery and rising demand for pharmaceutical products, particularly as the industry adapts to an aging population and increasing chronic disease prevalence.

Competitive Moat

characterized by scale economies and significant switching costs. As one of the largest pharmaceutical distributors, it benefits from operational efficiencies that smaller competitors cannot match, allowing it to negotiate better pricing from suppliers and pass those savings onto customers. The regulatory complexities associated with pharmaceutical distribution create high barriers to entry, further solidifying its position. Key competitive threats include rising competition from other large distributors like Cardinal Health and the potential for disruptive innovations in telehealth and direct-to-consumer drug delivery.

Growth Engine

Future revenue growth for McKesson is driven by its expansive total addressable market (TAM) in the pharmaceutical distribution segment, estimated to grow at a CAGR of 6% through 2030. The company is well-positioned to capitalize on this growth through geographic expansion in international markets and an increasing focus on specialty drugs and innovative healthcare solutions. McKesson has been gaining market share, particularly through its Prescription Technology Solutions segment, which addresses medication adherence challenges, thus enhancing its service offerings and customer relationships.